DGCR8: A Drug Target / Disease Biomarker (G54487)

Target Name: DGCR8

NCBI ID: G54487

DGCR8

DGCR8: A Drug Target / Disease Biomarker

DGCR8, also known as DGCR8-T1, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is doublecortin receptor subfamily 8 member 8. DGCR8 is a G protein-coupled receptor, which means it has a protein called G protein that interacts with a specific G protein-coupled receptor on the surface of a cell.

The DGCR8 protein is involved in a variety of physiological processes in the body, including modulating pain perception, insulin sensitivity, and inflammation. It is also involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the main functions of DGCR8 is its role in pain perception. DGCR8 is known to play a role in the regulation of pain signaling in the brain, and is involved in the production of pain signals. Studies have shown that DGCR8 is involved in the development of neuropathic pain, which is often difficult to treat and can be chronic and debilitating.

DGCR8 is also involved in modulating insulin sensitivity, which is important for maintaining healthy blood sugar levels and for preventing the development of type 2 diabetes. Insulin sensitivity is regulated by DGCR8 through a complex signaling pathway that involves the interaction of DGCR8 with several intracellular signaling pathways, including the PI3K/Akt signaling pathway.

DGCR8 is also involved in the regulation of inflammation, which is a critical aspect of many diseases, including cancer and neurodegenerative diseases. Inflammation is regulated by DGCR8 through the production of pro-inflammatory cytokines, which are involved in the recruitment of immune cells to the site of inflammation.

In addition to its role in pain perception, insulin sensitivity, and inflammation, DGCR8 is also involved in the regulation of other physiological processes, including sleep-wake cycles, cell survival, and neurotransmitter signaling.

DGCR8 is a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, DGCR8 has been shown to be involved in the development of neuropathic pain, and may be a useful target for treating neuropathic pain. Additionally, DGCR8 has been shown to be involved in the regulation of insulin sensitivity, and may be a useful target for treating insulin-related diseases.

In conclusion, DGCR8 is a protein that is involved in a variety of physiological processes in the body, including modulating pain perception, insulin sensitivity, and inflammation. It is also involved in the regulation of sleep-wake cycles, cell survival, and neurotransmitter signaling. As a potential drug target, DGCR8 may be a useful target for treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Further research is needed to fully understand the role of DGCR8 in these diseases and to develop effective treatments.

Protein Name: DGCR8 Microprocessor Complex Subunit

Functions: Component of the microprocessor complex that acts as a RNA- and heme-binding protein that is involved in the initial step of microRNA (miRNA) biogenesis. Component of the microprocessor complex that is required to process primary miRNA transcripts (pri-miRNAs) to release precursor miRNA (pre-miRNA) in the nucleus. Within the microprocessor complex, DGCR8 function as a molecular anchor necessary for the recognition of pri-miRNA at dsRNA-ssRNA junction and directs DROSHA to cleave 11 bp away form the junction to release hairpin-shaped pre-miRNAs that are subsequently cut by the cytoplasmic DICER to generate mature miRNAs (PubMed:26027739, PubMed:26748718). The heme-bound DGCR8 dimer binds pri-miRNAs as a cooperative trimer (of dimers) and is active in triggering pri-miRNA cleavage, whereas the heme-free DGCR8 monomer binds pri-miRNAs as a dimer and is much less active. Both double-stranded and single-stranded regions of a pri-miRNA are required for its binding (PubMed:15531877, PubMed:15574589, PubMed:15589161, PubMed:16751099, PubMed:16906129, PubMed:16963499, PubMed:17159994). Specifically recognizes and binds N6-methyladenosine (m6A)-containing pri-miRNAs, a modification required for pri-miRNAs processing (PubMed:25799998). Involved in the silencing of embryonic stem cell self-renewal (By similarity)

The "DGCR8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DGCR8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets